Georgia's Online Cancer Information Center

Find A Clinical Trial

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

Cancer Type
Colon/Rectal Cancer
Liver Cancer / Hepatoblastoma
Lung Cancer
Trial Phase
Phase I
18 Years and older, Male and Female
Study Type
Protocol IDs
CA102-003 (primary)
Study Sponsor
Bristol-Myers Squibb


The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels
and preliminary antitumor activity of BMS-986416 when administered alone and in combination
with Nivolumab in participants with select advanced solid tumors.


  1. Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor
  2. Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC), Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal adenocarcinoma (PDAC)
  3. Resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit
  4. Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
  5. Disease amenable to serial biopsy
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE


Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.